RE:RE:RE:This is why it popped Lifeboat, thanks for the article. Very much appreciated. As you mentioned, the article itself is a bit dated (p/rev multiples are probably much higher now) and these companies are mostly larger. Here are a few small and more local Saas/telehealth/tech stocks that came to mind:
Healthspace (HS, CSE) - not profitable, trading at 18.4x ttm rev, 15.0x annualized latest Q rev
CloudMD (DOC, TSXV) - not profitable, trading at 34.9x ttm rev, 30.3x annualized latest Q rev
vitalhub (VHI, TSXV) - not profitable, trading at 9.4x ttm rev, 8.34x annulaized latest Q rev
All of these companies have established revenue; whereas, RHT is just at the beginning of a potentially much steeper growth curve.
Lifeboat wrote: SaaS companies are generally valued on multiples of revenue at around 8.91x in 2018.
https://about.crunchbase.com/blog/saas-valuations/
Even those at 20x multiples of revenue are not always profitable but are generally cashflow positive with growth >30%. If Reliq can be profitable, cash flow positive and grow over 50% a year there is no reason the multiples should not be over 20x revenue based on comparables. And the current premium the market is giving on top of that for telehealth stocks.
100 million in Revenue x 20 / 200 million shares = $10